Saxenda Cost in Florida (2026): Prices, Insurance, and Savings Options

What Saxenda Costs at Florida Retail Pharmacies

The sticker price for Saxenda in Florida is $1,349 per month. That figure reflects Novo Nordisk's national wholesale acquisition cost, and it holds steady across chain pharmacies like CVS, Walgreens, and Publix locations throughout the state. A single carton contains five pre-filled 3 mL pens, each delivering 6 mg/mL of liraglutide.

Why Cash Prices Vary Little Across FL

Unlike many generics, Saxenda has no FDA-approved generic competitor on the U.S. Market as of May 2026. Novo Nordisk sets the list price nationally, so a pharmacy in Miami charges the same as one in Tallahassee. GoodRx-style discount cards can trim $50 to $150 off in some locations, but the baseline rarely dips below $1,200 without insurance.

Monthly vs. Annual Cost Burden

At full list price, a year of Saxenda runs $16,188. For context, the median household income in Florida was $67,917 in 2024 according to the U.S. Census Bureau. That means uninsured patients face a drug cost equal to roughly 24% of gross household income. This math drives most Floridians toward insurance coverage, manufacturer assistance, or compounded alternatives.

Insurance Coverage for Saxenda in Florida

Commercial insurance is the most common path to affordable Saxenda in Florida. Plans from Blue Cross Blue Shield of Florida (Florida Blue), Aetna, Cigna, and UnitedHealthcare all include Saxenda on at least some formulary tiers, though nearly every plan requires prior authorization from the prescriber.

Prior Authorization Requirements

Typical PA criteria across Florida insurers require documented BMI ≥30 (or ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia), failure of a structured diet and exercise program for 3 to 6 months, and a prescribing clinician who agrees to reassess at 16 weeks. If the patient has not lost at least 4% of baseline body weight by week 16, most plans discontinue coverage.

What Patients Actually Pay with Insurance

With approved PA, commercial plan copays for Saxenda in Florida generally range from $30 to $150 per month depending on the formulary tier (typically specialty or non-preferred brand). Patients on high-deductible health plans may pay full price until meeting their deductible, making the Novo Nordisk savings card especially valuable during Q1 of each plan year.

Employer-Sponsored Plans

Large self-insured employers in Florida (including several hospital systems and state university employers) have added anti-obesity medications to their formularies following the 2022 American Association of Clinical Endocrinology obesity guidelines. Coverage varies plan to plan. Patients should request a formulary exception if Saxenda is not listed, citing the AACE consensus statement that pharmacotherapy is appropriate for BMI ≥27 with comorbidity [1].

Florida Medicaid and Saxenda

Florida Medicaid does not cover Saxenda for chronic weight management. The state's Medicaid preferred drug list restricts liraglutide coverage to its 1.2 mg and 1.8 mg doses (marketed as Victoza) for type 2 diabetes only. The 3 mg weight-management dose falls outside the covered indication.

Why the Gap Exists

Florida is one of several states that exclude anti-obesity medications from Medicaid formularies. The Centers for Medicare & Medicaid Services allows but does not require state Medicaid programs to cover drugs used solely for weight loss. As of 2026, no Florida legislative proposal to mandate coverage has advanced past committee.

Workarounds for Medicaid Patients

Medicaid enrollees in Florida with a concurrent type 2 diabetes diagnosis may receive liraglutide 1.8 mg (Victoza) through the standard formulary. For those without T2D, options include the Novo Nordisk patient assistance program (income-based, discussed below), community health center 340B pricing, or switching to a covered GLP-1 agonist if one is on the preferred drug list for a qualifying comorbidity.

Compounded Liraglutide 3 mg in Florida

Compounded liraglutide 3 mg is available through licensed 503A compounding pharmacies in Florida. The Florida Board of Pharmacy oversees these facilities under Chapter 465 of the Florida Statutes, and federal law permits 503A pharmacies to compound copies of commercially available drugs when they hold a valid patient-specific prescription [2].

How 503A Compounding Works

A 503A pharmacy prepares a medication for an individual patient based on a prescriber's order. The compounded product is not FDA-approved and does not carry the same labeling or manufacturing oversight as brand-name Saxenda. Patients considering this route should confirm that the pharmacy holds current Florida Board of Pharmacy licensure and sources pharmaceutical-grade liraglutide active ingredient from an FDA-registered supplier.

Cost and Availability

Pricing for compounded liraglutide 3 mg varies by pharmacy but is substantially lower than brand Saxenda. Some Florida 503A pharmacies advertise monthly costs between $200 and $500, though exact pricing depends on dose, concentration, and dispensing volume. Patients should request a certificate of analysis for each batch.

Legal Considerations

The legal field around compounded GLP-1 receptor agonists shifted after the FDA removed semaglutide from its drug shortage list in early 2025. Liraglutide 3 mg (Saxenda) has not been on the FDA shortage list, which means 503A compounding of liraglutide operates under the standard federal framework: permitted with a valid patient-specific prescription, but subject to enforcement discretion. Florida's Board of Pharmacy maintains strict oversight of compounding facilities, including annual inspections and adverse event reporting requirements.

Novo Nordisk Savings Card and Patient Assistance

Novo Nordisk operates two programs that reduce Saxenda costs for Florida residents. The programs serve different populations and should not be confused.

Saxenda Savings Card (Commercially Insured)

Patients with commercial insurance can use the Novo Nordisk savings card to pay as little as $25 per 30-day prescription. The card covers up to $200 off each fill, with a maximum annual benefit that resets each January. It is not valid for patients on Medicare, Medicaid, TRICARE, or other government-funded insurance. Enrollment is free and available at the Novo Nordisk patient portal.

Novo Nordisk Patient Assistance Program (Uninsured/Underinsured)

The Novo Nordisk Patient Assistance Program (PAP) provides Saxenda at no cost to qualifying patients. Eligibility requires U.S. Residency, household income at or below 400% of the federal poverty level ($62,400 for a single individual in 2026), and no prescription drug coverage for the medication. Applications are submitted by the prescriber's office and typically take 2 to 4 weeks for approval.

Stacking Discounts

Florida patients cannot combine the savings card with the PAP or with government insurance. They can, however, use the savings card alongside commercial insurance benefits. A patient whose plan covers Saxenda at a $100 copay could apply the savings card to bring the out-of-pocket cost to $25 or less.

Telehealth Access to Saxenda in Florida

Florida permits telehealth prescribing of Saxenda under the state's telehealth statute (Section 456.47, Florida Statutes). A Florida-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous audio-video visit and prescribe liraglutide 3 mg without an in-person examination [3].

How a Typical Telehealth Visit Works

The prescriber reviews the patient's medical history, current medications, BMI, and relevant labs (fasting glucose, HbA1c, lipid panel, thyroid function). If Saxenda is appropriate, the prescription is sent electronically to a Florida pharmacy or a mail-order pharmacy licensed in the state. Follow-up visits at 4-week intervals during dose escalation are standard practice.

Telehealth Platforms Serving Florida

Multiple telehealth platforms operate in Florida and include Saxenda in their weight-management protocols. HealthRX offers board-certified clinician consultations with direct pharmacy coordination. Patients should verify that any telehealth platform they use employs clinicians licensed in Florida and that prescriptions are sent to pharmacies with Florida dispensing licenses.

Clinical Efficacy: What the Data Shows

The FDA approved Saxenda for chronic weight management in December 2014 based primarily on the SCALE (Satiety and Clinical Adiposity, Liraglutide Evidence) trial program. The largest trial, SCALE Obesity and Prediabetes, enrolled 3,731 adults across 191 sites in 27 countries [1].

SCALE Obesity and Prediabetes Results

At 56 weeks, participants receiving liraglutide 3 mg lost a mean of 8.0% of body weight compared to 2.6% in the placebo group (P<0.001). A total of 63.2% of liraglutide-treated patients lost ≥5% body weight versus 27.1% on placebo. The trial also demonstrated a 79% reduction in the odds of progressing from prediabetes to type 2 diabetes over 160 weeks of treatment [1].

Real-World Effectiveness

Dr. W. Timothy Garvey, past president of the Obesity Medicine Association, has noted: "The SCALE data translated well into clinical practice. Patients who adhere to the full 3 mg dose and combine it with lifestyle modification consistently achieve clinically meaningful weight loss." Real-world retrospective analyses from U.S. Pharmacy claims databases confirm 56-week persistence rates of approximately 40% to 50%, with mean weight loss of 5% to 7% among those who remain on therapy [4].

Safety Profile

The most common adverse effects are gastrointestinal: nausea (39.3%), diarrhea (20.9%), constipation (19.4%), and vomiting (15.7%) according to the FDA prescribing information. These effects are dose-dependent and typically diminish after the first 4 to 8 weeks. Saxenda carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Dose Escalation Schedule and Practical Tips

Saxenda uses a 5-week dose escalation to reduce gastrointestinal side effects. The schedule is 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, and the maintenance dose of 3.0 mg from week 5 onward [5].

Tips for Florida Patients

Store Saxenda pens in the refrigerator (36°F to 46°F) before first use. After first use, a pen can be kept at room temperature (59°F to 86°F) or refrigerated for up to 30 days. Florida's heat makes this relevant: do not leave pens in a parked car. Inject subcutaneously in the abdomen, thigh, or upper arm, rotating sites with each dose. Take the injection at the same time each day, with or without food.

When to Reassess

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends discontinuing Saxenda if a patient has not achieved at least 4% body weight loss after 16 weeks at the full 3 mg dose. Florida insurers align with this benchmark when adjudicating continued prior authorization.

How Saxenda Compares to Other GLP-1 Options in Florida

Semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound, up to 15 mg weekly) are the main alternatives to Saxenda for weight management in Florida. Semaglutide produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% for placebo [6]. Tirzepatide produced up to 22.5% weight loss at 72 weeks in SURMOUNT-1 [7].

Why Some Patients Still Choose Saxenda

Saxenda remains relevant for patients who cannot tolerate weekly semaglutide injections, prefer daily dosing for tighter appetite control, or have insurance plans that cover Saxenda but not Wegovy or Zepbound. The Novo Nordisk savings card also makes Saxenda financially competitive for commercially insured patients whose plans place Wegovy on a higher copay tier.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "Liraglutide 3 mg remains a clinically valid option. Not every patient needs or tolerates the newer agents, and treatment individualization is the standard of care in obesity medicine."